Acrivon Posts Narrower Q2 Loss, $90M Cash Runway Into Q4 2027; Key ACR-368 Data Due H2 2026
ACRV sits 42% above its 52-week low of $1.21 on light trading volume (0.4× avg).
Summary
Acrivon reported Q2 2026 net loss of $18.0M, down from $21.0M a year ago, with R&D spend of $13.8M versus $16.2M. Cash stands at $90.0M as of June 30, 2026, funding operations into Q4 2027. The company confirmed the prespecified interim analysis for ACR-368 in all-comer serous endometrial cancer remains on track for H2 2026, with Phase 3 initiation planned for H1 2027. ACR-2316 has entered randomized dose expansion in lung, endometrial, cervical, and esophago-gastric cancers, supported by durable responses in heavily pretreated patients. The CDK11 inhibitor program is advancing toward an IND filing in H1 2027.
At the time of this announcement, ACRV was trading at $1.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.6M. The 52-week trading range was $1.21 to $3.56. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.